Article
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
Journal of virology - 1 Mar 1994
Ho D D, Toyoshima T, Mo H, Kempf D J, Norbeck D, Chen C M, Wideburg N E, Burt S K, Erickson J W, Singh M K
Abstract excerpt
Inhibitors of the human immunodeficiency virus type 1 protease represent a promising class of antiviral drugs for the treatment of AIDS, and several are now in clinical trials. Here, we report the in vitro selection of viral variants with decreased sensitivity to a C2-symmetric protease inhibitor...
Topics
- Amino Acid Sequence
- Antiviral Agents
- Base Sequence
- Dose-Response Relationship, Drug
- Drug Design
- Drug Resistance, Microbial
- Genetic Variation
- HIV Protease
- HIV Protease Inhibitors
- HIV-1
- Methylurea Compounds
- Models, Molecular
- Molecular Sequence Data
- Pyridines